Shattuck Labs Inc
STTK3.770USD
+0.200+5.60%
收盘 02/06, 16:00（美东）报价延迟15分钟
238.08M总市值
亏损市盈率 TTM
关于 Shattuck Labs Inc 公司
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Shattuck Labs Inc简介
公司代码STTK
公司名称Shattuck Labs Inc
上市日期Oct 09, 2020
CEOSchreiber (Taylor)
员工数量44
证券类型Ordinary Share
年结日Oct 09
公司地址500 W. 5Th Street
城市AUSTIN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编78701
电话15129004690
网址https://www.shattucklabs.com/
公司代码STTK
上市日期Oct 09, 2020
CEOSchreiber (Taylor)
Shattuck Labs Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+25610.00%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
81.53K
-4746.00%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Mr. Conor Richardson, CPA
Mr. Conor Richardson, CPA
Senior Director, Finance & Investor Relations
Senior Director, Finance & Investor Relations
--
--
Dr. Abhinav A. Shukla, Ph.D.
Dr. Abhinav A. Shukla, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Clay Siegall, Ph.D.
Dr. Clay Siegall, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel G. (Dan) Baker, M.D.
Dr. Daniel G. (Dan) Baker, M.D.
Independent Director
Independent Director
--
--
Dr. Mona Ashiya, Ph.D.
Dr. Mona Ashiya, Ph.D.
Director
Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+25610.00%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
81.53K
-4746.00%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Mr. Conor Richardson, CPA
Mr. Conor Richardson, CPA
Senior Director, Finance & Investor Relations
Senior Director, Finance & Investor Relations
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 1月30日 周五
更新时间: 1月30日 周五
持股股东
股东类型
持股股东
持股股东
占比
T. Rowe Price Investment Management, Inc.
11.65%
OrbiMed Advisors, LLC
9.97%
Adage Capital Management, L.P.
9.97%
Redmile Group, LLC
8.75%
Prosight Capital
8.61%
其他
51.05%
持股股东
持股股东
占比
T. Rowe Price Investment Management, Inc.
11.65%
OrbiMed Advisors, LLC
9.97%
Adage Capital Management, L.P.
9.97%
Redmile Group, LLC
8.75%
Prosight Capital
8.61%
其他
51.05%
股东类型
持股股东
占比
Hedge Fund
23.34%
Investment Advisor
17.02%
Investment Advisor/Hedge Fund
14.68%
Private Equity
9.97%
Corporation
9.51%
Family Office
2.58%
Research Firm
2.11%
Individual Investor
1.80%
Venture Capital
0.04%
其他
18.95%
机构持股
更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
186
35.95M
56.82%
+4.07M
2025Q3
179
32.72M
51.71%
-1.24M
2025Q2
186
35.33M
73.76%
-6.35M
2025Q1
190
36.10M
75.45%
-5.76M
2024Q4
182
37.00M
77.49%
-7.77M
2024Q3
191
41.87M
87.75%
-1.86M
2024Q2
194
39.66M
83.35%
+16.66K
2024Q1
209
37.10M
79.60%
-1.39M
2023Q4
203
34.54M
71.04%
+5.75M
2023Q3
205
27.35M
64.28%
-7.93M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
OrbiMed Advisors, LLC
6.31M
9.97%
+6.31M
--
Sep 30, 2025
Adage Capital Management, L.P.
6.31M
9.97%
+1.63M
+34.89%
Sep 30, 2025
Redmile Group, LLC
5.54M
8.75%
--
--
Sep 30, 2025
Prosight Capital
5.45M
8.61%
-1.19M
-17.89%
Sep 30, 2025
Hornblower Capital Holdings, LLC
2.89M
4.57%
--
--
Apr 01, 2025
Houghton Capital Holdings, LLC
2.61M
4.13%
--
--
Apr 01, 2025
The Vanguard Group, Inc.
2.13M
3.36%
-19.77K
-0.92%
Sep 30, 2025
683 Capital Management LLC
1.53M
2.42%
+437.22K
+39.93%
Sep 30, 2025
The Clark Estates Inc.
1.48M
2.33%
--
--
Sep 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Texas Capital Texas Equity Index ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares UltraPro Russell2000
0%
Dimensional US Core Equity 1 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Morningstar Small-Cap ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Texas Capital Texas Small Cap Equity Index ETF
0%
查看更多
Texas Capital Texas Equity Index ETF
占比0%
iShares Russell 2000 Value ETF
占比0%
ProShares UltraPro Russell2000
占比0%
Dimensional US Core Equity 1 ETF
占比0%
ProShares Hedge Replication ETF
占比0%
iShares Morningstar Small-Cap ETF
占比0%
iShares Russell 2000 ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
iShares Micro-Cap ETF
占比0%
Texas Capital Texas Small Cap Equity Index ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
